Nabriva Therapeutics Ag Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Nabriva |
Nabriva Therapeutics AG Company Z Score Analysis
Nabriva Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Nabriva Therapeutics Z Score | -32.68 |
Most of Nabriva Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionBased on the company's disclosures, Nabriva Therapeutics AG has a Z Score of -32.68. This is 584.15% lower than that of the Pharmaceuticals sector and notably lower than that of the Health Care industry. The z score for all United States stocks is notably higher than that of the company.
Nabriva Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nabriva Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nabriva Therapeutics could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics of similar companies.Nabriva Therapeutics is currently under evaluation in z score category among its peers.
Nabriva Fundamentals
Return On Equity | -2.69 | |||
Return On Asset | -0.65 | |||
Profit Margin | (1.48) % | |||
Operating Margin | (1.29) % | |||
Current Valuation | 3.29 M | |||
Shares Outstanding | 3.2 M | |||
Shares Owned By Insiders | 0.96 % | |||
Shares Owned By Institutions | 8.77 % | |||
Number Of Shares Shorted | 44.59 K | |||
Price To Earning | (0.48) X | |||
Price To Book | 0.24 X | |||
Price To Sales | 0.17 X | |||
Revenue | 35.67 M | |||
Gross Profit | (10.23 M) | |||
EBITDA | (54.7 M) | |||
Net Income | (57.19 M) | |||
Cash And Equivalents | 20.04 M | |||
Cash Per Share | 7.53 X | |||
Total Debt | 5.22 M | |||
Debt To Equity | 0.21 % | |||
Current Ratio | 2.81 X | |||
Book Value Per Share | (1.36) X | |||
Cash Flow From Operations | (36.71 M) | |||
Short Ratio | 8.58 X | |||
Earnings Per Share | (19.67) X | |||
Price To Earnings To Growth | (0.06) X | |||
Target Price | 1.0 | |||
Number Of Employees | 39 | |||
Beta | 1.56 | |||
Market Capitalization | 4.55 M | |||
Total Asset | 31.77 M | |||
Retained Earnings | (652.86 M) | |||
Working Capital | 3.5 M | |||
Current Asset | 83 M | |||
Current Liabilities | 14 M | |||
Z Score | -32.68 | |||
Net Asset | 31.77 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Transaction History View history of all your transactions and understand their impact on performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |